Robert Hazlett
Stock Analyst at BTIG
(0.56)
# 3,923
Out of 4,876 analysts
23
Total ratings
33.33%
Success rate
-23.99%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.29 | +281.56% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $29.68 | +102.16% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.52 | +2,607.93% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $13.38 | +7,373.84% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $102.57 | -4.46% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $4.16 | +1,342.31% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $2.66 | +2,268.42% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $6.18 | +369.26% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.82 | +1,428,471.43% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.74 | +60.43% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.50 | +56.52% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.29
Upside: +281.56%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $29.68
Upside: +102.16%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.52
Upside: +2,607.93%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $13.38
Upside: +7,373.84%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $102.57
Upside: -4.46%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $4.16
Upside: +1,342.31%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $2.66
Upside: +2,268.42%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $6.18
Upside: +369.26%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.82
Upside: +1,428,471.43%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.74
Upside: +60.43%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $11.50
Upside: +56.52%